drugset / Trial / NCT06547502

Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment

NCT06547502

Phase 1 Completed 16 enrolled Gan and Lee Pharmaceuticals, USA
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will be conducted to investigated the effect of decreased kidney function on PK and safety of GZR4 and to guide dosing recommendations in people with kidney impairment.

Timeline

Start
2024-07-03
Primary completion
2024-08-20
Completion
2024-09-05

Drugs

EvaluationDrugModalityDoseRoute
Subject GZR4 Unknown

Indications